{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:32:32Z","timestamp":1793971952800,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.esmoop.2023.101576","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:18:52Z","timestamp":1686129532000},"page":"101576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial"],"prefix":"10.1016","volume":"8","author":[{"given":"N.","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ponce Aix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cedres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Berghmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Toffart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hochstenbag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Prosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Xenophontos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Pretzenbaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1016\/j.esmoop.2023.101576_bib1","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0394-2020","article-title":"Thymic tumours and their special features","volume":"30","author":"Basse","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.esmoop.2023.101576_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejso.2018.01.078","article-title":"Mesothelioma and thymic tumors: treatment challenges in (outside) a network setting","volume":"45","author":"Imbimbo","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib4","series-title":"World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart","article-title":"WHO histological classification of tumours of the thymus","year":"2015"},{"key":"10.1016\/j.esmoop.2023.101576_bib5","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic therapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort","volume":"13","author":"Merveilleux du Vignaux","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ctrv.2018.10.001","article-title":"Best practices for the management of thymic epithelial tumors: a position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)","volume":"71","author":"Imbimbo","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2023.101576_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2017.11.118","article-title":"Paraneoplastic syndromes and thymic malignancies: an examination of the International Thymic Malignancy Interest Group retrospective database","volume":"13","author":"Padda","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib8","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jtho.2016.07.018","article-title":"Response to pembrolizumab in a patient with relapsing thymoma","volume":"11","author":"Zander","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.iotech.2019.09.002","article-title":"Immune checkpoints in thymic epithelial tumors: challenges and opportunities","volume":"3","author":"Girard","year":"2019","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.esmoop.2023.101576_bib10","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.18632\/oncotarget.24075","article-title":"A\u00a0comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma","volume":"9","author":"Sakane","year":"2018","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101576_bib11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/oncolo\/oyac115","article-title":"Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers","volume":"27","author":"Girard","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2023.101576_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2023.101576_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101576_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib16","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1200\/jco.2006.24.18_suppl.7079","article-title":"A\u00a0phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loehrer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2019.09.015","article-title":"Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies","volume":"137","author":"Hellyer","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2023.101576_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A\u00a0multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib19","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101576_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","article-title":"A\u00a0phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21)","volume":"18","author":"Jung","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2021.11.028","article-title":"Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network","volume":"162","author":"Petat","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101576_bib23","first-page":"S604","article-title":"Pan-European survey on thymic malignancies: a collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network","volume":"51","author":"Menis","year":"2015","journal-title":"Eur J"},{"issue":"9 suppl 2","key":"10.1016\/j.esmoop.2023.101576_bib24","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/JTO.0000000000000296","article-title":"A\u00a0practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria","volume":"9","author":"Benveniste","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib26","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101576_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100188","article-title":"Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)","volume":"6","author":"Conforti","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.101576_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.esmoop.2023.101576_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2023.101576_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2020.11.011","article-title":"Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: a RYTHMIC study","volume":"143","author":"Molina","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101576_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jclinpath-2017-204788","article-title":"PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus","volume":"71","author":"Bagir","year":"2018","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.esmoop.2023.101576_bib35","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.esmoop.2023.101576_bib36","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101576_bib37","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.cllc.2021.07.008","article-title":"PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients","volume":"23","author":"Remon","year":"2022","journal-title":"Clin Lung Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:32:55Z","timestamp":1761856375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923008086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2059702923008086"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101576","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101576"}}